Gap-Scheduled Olaparib Plus Neoadjuvant Chemotherapy Improved Survival in Patients With gBRCAm TBNC

Source: Pharmacy Times articles

Combining olaparib with neoadjuvant chemotherapy enhances survival rates for early-stage gBRCAm triple-negative breast cancer, offering new hope for patients.
Read More